1. ALLA AKTIER
  2. NYHETER
  3. EGETIS THERAPEUTICS

Egetis Therapeutics

Nyheter Egetis Therapeutics Nyheter alla bolag
Affiliate
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här
Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

Changes in number of shares and votes in Egetis Therapeutics

LHFI

Stockholm, Sweden, September 30, 2026. The number of shares and votes in Egetis Therapeutics AB (publ) (“Egetis Therapeutics” or the “Company”) (Nasdaq Stockholm: EGTX) has changed in September as a result of the exercise of employee stock options granted under the 2022–2026 and 2023-2026 employee stock option programs.

The total number of shares in the Company is unchanged at 490,828,605, but the number of ordinary shares has increased by 18,338, from 464,947,224 to 464,965,562 and the number of C shares has decreased by 18,338, from 25,881,381 to 25,863,043. The total number of votes in the Company has increased by 16,504.2, from 467,535, 362.1 to 467,551,866.3.
The share capital is unchanged at approximately SEK 25,833,094.110797.

For further information, please contact:

Karl Hård, Head of Investor Relations & Business Development
+46 (0) 733 011 944
karl.hard@egetis.com 

About Egetis Therapeutics

Egetis Therapeutics is a commercial-stage pharmaceutical company focused on developing and delivering innovative therapies for patients with rare diseases with significant unmet medical need. Combining scientific and clinical expertise with integrated late-stage development, regulatory and commercial capabilities and manufacturing expertise, Egetis is committed to delivering treatments and dedicated support to underserved patient communities.
The Company's lead product, EMCITATE® (tiratricol), is the first and only approved treatment for MCT8 deficiency, a rare and life-shortening genetic disorder, with marketing authorizations in the European Union and in the United States.
Headquartered in Stockholm, Sweden, with operations in the U.S. and Europe, Egetis is building a sustainable global rare disease company.
For more information, visit egetis.com and follow the Company on LinkedIn.

This information is information that Egetis Therapeutics is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2026-09-30 18:00 CEST.

Attachments

Changes in number of shares and votes in Egetis Therapeutics

Datum 2026-09-30, kl 18:00
Källa MFN
Bifogade filer
Changes in number of shares and votes in Egetis Therapeutics